Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-05-2011 | Review Article

The production of [¹²⁴I]iodine and [⁸⁶Y]yttrium

Author: Jochen Schmitz

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Special Issue 1/2011

Abstract

The use of paired tracers such as ¹²⁴I/¹³¹I and ⁸⁶Y/⁹⁰Y allows pretherapy PET imaging with positron emitting radioisotopes of the same element as used for therapy. Whereas nowadays most therapy nuclides are produced by reactors or generators, the production of the corresponding PET isotopes requires the irradiation of adequate targets using particle accelerators such as cyclotrons. This paper describes the production routes for ¹²⁴I and ⁸⁶Y.

Ott RJ. Imaging technologies for radionuclide dosimetry. Phys Med Biol. 1996;41:1885–94.PubMedCrossRef

Blasberg RG, Roelcke U, Weinreich R, von Ammon K, Crompton N, Günther I, et al. [124I]Iododeoxyuridine imaging tumor proliferation. J Nucl Med. 1996;37 Suppl:P59.

Wilson CB, Snook DE, Dhokia B, Taylor CV, Watson IA, Lammertsma AA, et al. Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and 124iodine in patients with breast cancer. Int J Cancer. 1991;47:344–7.PubMedCrossRef

Langen KJ, Coenen HH, Roosen N, Kling P, Muzik O, Herzog H, et al. SPECT studies of brain tumors with L-3-[123I] iodo-alpha-methyl tyrosine: comparison with PET, 124IMT and first clinical results. J Nucl Med. 1990;31:281–6.PubMed

Frey P, Townsend D, Falattet A, De Gautard R, Widgren S, Jeavons A, et al. Tomographic imaging of the human thyroid using 124I. J Clin Endocrinol Metab. 1986;63:918–27.PubMedCrossRef

Stepanek J, Larsson B, Weinreich R. Auger-electron spectra of radionuclides for therapy and diagnostics. Acta Oncol. 1996;35:863–8.PubMedCrossRef

Freudenberg L, Jentzen W, Görges R, Petrich T, Marlowe RJ, Knust J, et al. 124I-PET-dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin. 2007;46:121–8.PubMed

Ott RJ, Tait D, Flower MA, Babich JW, Lambrecht RM. Treatment panning for I-131-mIBG radiotherapy of neural crest tumours using I-124-mIBG positron emission tomography. Br J Radiol. 1992;65:787–91.PubMedCrossRef

Kondo K, Lambrecht RM, Norton EF, Wolf AP. Cyclotron isotopes and radiopharmaceuticals--XXII. Improved targetry and radiochemistry for production of 123I and 124I. Int J Appl Radiat Isot. 1977;28:765–71.PubMedCrossRef

10.

Akbari RB, Ott RJ, Trott NG, Sharma HL, Smith AG. Radionuclide purity and radiation dosimetry of 124I used in positron tomography of the thyroid. Phys Med Biol. 1986;31:789–91.PubMedCrossRef

11.

Lambrecht RM, Sajjad M, Qureshi MA, Al-Yanbawi SJ. Production of iodine-124. J Radioanal Nucl Chem Lett. 1988;127:143–50.CrossRef

12.

International Atomic Energy Agency. Charged particle cross-section database for medical radioisotope production: diagnostic radioisotopes and monitor reactions, IAEA-TECDOC-1211, 2001; IAEA, Vienna

13.

Scholten B, Kovács Z, Tárkány F, Qaim SM. Excitation functions 124Te(p,xn)124,123I reactions from 6 to 31 MeV with special reference to the production of 124I at small cyclotron. Appl Radiat Isot. 1995;46:255–9.CrossRef

14.

Firouzbakht ML, Schlyer DJ, Wolf AP. The yield of I-124 from different target materials in the 124Te(d,2n)124I reaction and improved recovery method for Te-124. J Labelled Comp Radiopharm. 1994;35:257–9.

15.

Van den Bosch R, De Goeij JJ, Van der Heide JA, Tertoolen JF, Theelen HM, Zegers C. A new approach to target chemistry for the iodine-123 production via the 124Te(p,2n) reaction. Int J Appl Radiat Isot. 1977;28:255–61.PubMedCrossRef

16.

Shikata E, Amano H. Dry distillation of iodine-131 from several tellurium compounds. J Nucl Sci Technol. 1973;10:80–8.CrossRef

17.

Knust EJ, Dutschka K, Weinreich R. Preparation of 124I solutions after thermodistillation of irradiated 124TeO2 targets. Appl Radiat Isot. 2000;52:181–4.PubMedCrossRef

18.

Förster GJ, Engelbach M, Brockmann J, Reber HJ, Buchholz HG, Mäcke HR, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur J Nucl Med. 2001;28:1743–50.PubMedCrossRef

19.

Rösch F, Qaim SM, Stöcklin G. Production of the positron emitting radioisotope 86Y for nuclear medical applications. Int J Appl Radiat Isot. 1993;44:677–81.CrossRef

20.

Sachdev DR, Porile NT, Yaffe L. Reactions of Sr-88 with protons of energies 7-85 MeV. Can J Chem. 1967;45:1149–60.CrossRef

Title: The production of [124I]iodine and [86Y]yttrium
Author: Jochen Schmitz
Publication date: 01-05-2011
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue Special Issue 1/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1782-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The production of [¹²⁴I]iodine and [⁸⁶Y]yttrium

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2011

Absolute quantification in SPECT

Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer

Preclinical animal research on therapy dosimetry with dual isotopes

Quantitative imaging of 124I and 86Y with PET

Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer

Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies